In recent days, the largest international conference on oncology, the ASCO, has ended.
The conference presents results from studies with new cancer drugs and studies with known cancer drugs that are also used in various cancers.
These are non-small cell lung cancer patients with non-small cell lung cancer (NSCLC) with PD-L1 over 1%.
Metastatic patients who started the first treatment for their metastatic disease with an immunotherapeutic drug called Keytruda extended life significantly longer than patients who received a combination of two conventional chemotherapies used in standard protocols.
- The study is called KEYNOTE-042 and these are the results for your impression:
- Lung cancer patients with PD-L1 above 50% lived nearly 8 months longer than patients treated with standard chemotherapy protocols.
- Lung cancer patients with PD-L1 over 20% lived longer than 5 months than patients treated with standard chemotherapy protocols.
- Lung cancer patients with PD-L1 above 1% lived longer than 5 months than patients treated with standard chemotherapy protocols.
- The side effects observed in the study with Keytruda compared with chemotherapy were far fewer.
Future and advanced cancer drugs with potential and longevity are available in clinical trials and other channels that are not standard protocols. Some cancer drugs can be accessed outside the framework of clinical trials and some are not.
Source:
2018 American Society of Clinical Oncology (ASCO) Annual Meeting news release ASCO.
All rights reserved to https://am.asco.org/
